​Michael A. Davies, MD, PhD, discusses the importance of identifying which patients diagnosed with melanoma are at the highest risk for developing brain metastases.
Michael A. Davies, MD, PhD, associate professor, deputy chair, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of identifying which patients diagnosed with melanoma are at the highest risk for developing brain metastases. He said this identification process is equally important in patients with early-stage disease as it is in patients with advanced melanoma.
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More